Overview

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

Status:
Not yet recruiting

Trial end date:
2024-04-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the ability of study participants with generalized Myasthenia Gravis (gMG) to successfully self-administer rozanolixizumab after training in the self-administration technique using the syringe driver and manual push methods.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

Rozanolixizumab